Phase 2 N=13 Safety and Efficacy of a Combination Product for the Prevention of Veisalgia
Veisalgia
Primary: Efficacy of Side Effect Prevention Using the Acute Hangover Scale — 6.7; 4.7; 7.8; 6.8 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=270 A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure — 2.79; 0.53 mmHg — p=<.001
Phase 2 N=45 A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
Symptomatic Focal Vitreomacular Adhesion
Primary: Release of Vitreo Macular Adhesion (VMA) by Optical Coherence Tomography (OCT) — 4; 0 Participants
Phase 2 N=14 Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Prostate Cancer
Primary: (Phase I) Maximum Tolerated Dose — 4000 mg
Phase 2 N=3 Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants
Phase 2 N=112 Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Unresected Stage IIIb to IVM1c Melanoma
Primary: Odds Ratio of Baseline Intratumoral CD8+ Cell Density and Objective Response Rate — 1.11 ratio — p=0.387
Phase 2 N=17 Adoptive Transfer of Haplo-identical DLI for AML and MDS
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Subjects With Unacceptable Toxicity — 1 Participants
Phase 2 N=44 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: Determine Pathologic Complete Response — 9 Participants
Phase 2 N=271 Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction
Anovulation
Primary: Ovulation Rate in Cycle 1 — 64.9; 30.4; 36.8; 35.9 percentage of subjects
Phase 2 N=17 Phase II Study of Tesetaxel in Metastatic Melanoma
Advanced Melanoma · Cancer
Primary: Response Rate (ie, the Percentage of Subjects With a Confirmed Complete or Partial Response) — 0; 0; 0; 0 percentage of participants
Phase 2 N=34 ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
Exudative Age-related Macular Degeneration
Primary: Percent of Eyes With Severe Ocular Adverse — 0; 0; 0 percentage of participants
Phase 2 N=21 Oral Nitrite for Older Heart Failure Patients
Heart Failure
Primary: Skeletal Muscle Bioenergetics- Polymerase Chain Reaction (PCR) — 12.04; 11.91; 11.79; 11.76 Relative Expression
Phase 2 N=18 Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Immune Response Following Treatment — 6; 5 Participants
Phase 2 N=113 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) · Rhabdomyosarcoma · Leiomyosarcoma
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants
Phase 2 N=43 A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With an Objective Overall Response — 6.1 percentage of participants